Use of fibrinogen and fibrin D-dimer in prediction of arterial thrombotic events

Thrombosis and Haemostasis

Volumn 82, Issue 2, 1999, Pages 667-672

  Lowe, Gordon D O ^a   Rumley, Ann ^a  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; D DIMER; FIBRINOGEN; WARFARIN;

ARTERY THROMBOSIS; ATHEROGENESIS; BLOOD VISCOSITY; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DISSEMINATED INTRAVASCULAR CLOTTING; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBRINOGEN BLOOD LEVEL; HUMAN; PREDICTION; PRIORITY JOURNAL;

EID: 0032724234     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1615895     Document Type: Conference Paper

References (62)

1. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med. 1993;118:956-963.
2. Heinrich H, Balleisen L, Schulte H, Assmann G, van de Loo J. Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM Study in healthy men. Arterioscler Thromb Vasc Biol. 1994;14:54-59.
3. Lowe GDO. Fibrinogen. A cardiovascular risk factor, 2d ed. Mannheim: Boehringer Mannheim; 1997.
4. Kannel EB, D'Agostino RB, Belanger AJ. Update of fibrinogen as a cardiovascular risk factor. Ann Epidemiol. 1992;2:457-466.
5. Kannel WB. Influence of fibrinogen on cardiovascular disease. Drugs. 1997;54(Suppl 3):32-40.
6. Danesh J, Collins R, Appleby P, Peto R. Fibrinogen, C-reactive protein, albumin or white cell count: meta-analyses of prospective studies of coronary heart disease. JAMA. 1998;279;1477-1482.
7. Woodward M, Lowe GDO, Rumley A, Tunstall-Pedoe H. Fibrinogen as a risk factor for coronary heart disease and mortality in middle aged men and women: The Scottish Heart Health Study. Eur Heart J. 1998;19:55-62.
8. Cortellaro M, Confrancesco E, Boschetti C, Mussoni L, Donati MB, Cardillo M, Catalano M, Gabrielli L, Lombardi B, Specchia G, et al. Increased fibrin turnover and high PAI-1 activity as predictors of ischaemic events in atherosclerotic patients: a case-control study. Arterioscler Thromb Vasc Biol. 1993;13:1412-1417.
9. Fowkes FGR, Lowe GDO, Housely E, Rattray A, Elton RA, MacGregor IR, Dawes J. Cross-linked fibrin degradation products, risk of coronary heart disease, and progression of peripheral arterial disease. Lancet. 1993;342:84-86.
10. Ridker PM, Hennekens CH, Cerskus A, Stampfer MH. Plasma concentration of cross-linked fibrin degradation products (D-dimer) and the risk of future myocardial infarction among apparently health men. Circulation. 1984;90:2236-2240.
11. Woodburn KR, Rumley A, Lowe GDO, Love JG, Murray GD, Pollock JG. Clinical, biochemical and rheologic factors affecting the outcome of infrainguinal bypass grafting. J Vasc Surg. 1996;24:639-646.
12. Smith FB, Lee AJ, Fowkes FGR, Rumley A, Lowe GDO. Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study. Arterioscler Thromb Vasc Biol. 1997;17:3321-3325.
13. Lowe GDO, Yarnell JWG, Sweetnam PM, Rumley A, Thomas HF, Elwood PC. Fibrin D-dimer, tissue plasminogen activator, plasminogen activator inhibitor, and the risk of major ischaemic heart disease in the Caerphilly Study. Thromb Haemost. 1998;79:129-133.
14. Smith FB, Rumley A, Lee AJ, Leng GL, Fowkes FGR, Lowe GDO. Haemostatic factors and prediction of ischaemic heart disease and stroke in claudicants. Br J Haematol. 1998;100:758-763.
15. Lip GYH, Lowe GDO. Fibrin D-dimer: a useful clinical marker of thrombogenesis? Clin Sci (Colch). 1995;89:205-214.
16. Bounameaux H, de Moerloose P, Perrier A, Miron M-J. D-dimer testing in suspected venous thromboembolism: an update. QJM. 1997;90:422-437.
17. Furlan M, Felix R, Escher N, Lämmle B. How high is the true fibrinogen content of fibrinogen standards? Thromb Res. 1989;56:583-592.
18. Gaffney PJ, Wong MY. Collaborative study of proposed international standard for plasma fibrinogen measurement. Thromb Haemost. 1992;68:428-432.
19. Lowe GDO. Haemostatic risk factors for arterial and venous thrombosis. In: Recent Advances in Blood Coagulation, 7. Poller L, Ludlam CA, eds. Edinburgh: Churchill Livingstone 1997;69-96.
20. Sweetnam PM, Yarnell JWG, Lowe GDO, Baker IA, O'Brien JR, Rumley A, Etherington MD, Whitehead PJ, Elwood PC. The relative power of heat-precipitation nephelometric and clottable (Clauss) fibrinogen in the prediction of ischaemic heart disease: the Caerphilly and Speedwell studies. Br J Haematol. 1998;100:582-588.
21. Lawrie AS, Mackie IJ, Kitchen, S, Howarth D, Martin J, Gaffney P, Rigsby P, Rumley A, Lowe G. An evaluation of popular Clauss and prothrombin time derived fibrinogen assay reagents. Blood Coag Fibrinolysis. 1999; 10, Suppl 1:s101-102.
22. Mackie IJ, Lawrie AS, Howarth D, Martin J, Rumley A, Lowe G, Gaffney P, Rigsby P, Kitchen S. The impact of commercial reference preparations on fibrinogen assays. Blood Coagul Fibrinolysis. 1999; 10, Suppl 1:s102.
23. Rumley A, Woodward M, Hoffmeister A, Koenig W, Lowe GDO. Comparison of three plasma fibrinogen assays in a random population sample. Blood Coagul Fibrinolysis. 1999; 10, Suppl 1:s102.
24. Gaffney PJ, Edgell T, Creighton-Kempsford LJ, Wheeler S, Tarelli E. Fibrin degradation product (FnDP) assays: analysis of standardisation issues and target antigens in plasma. Br J Haematol. 1995;90:187-194.
25. Lowe GDO. Agents lowering blood viscosity, including defibrinogenating agents. In: Cardiovascular Thrombosis, 2d ed. Verstralte M, Fuster V, Topol EJ, eds. Philadelphia: Lippincott-Raven 1998:321-333.
26. Lip GYH, Lowe GDO, Rumley A, Dunn FG. Increased markers of thrombogenesis in chronic atrial fibrillation: effects of warfarin treatment. Br Heart J. 1995;73:527-533.
27. Lip GYH, Lowe GDO, Metcalfe MJ, Rumley A, Dunn FG. Effects of warfarin therapy on plasma fibrinogen, von Willebrand factor, and fibrin D-dimer in left ventricular dysfunction secondary to coronary artery disease with and without aneurysms. Am J Cardiol. 1995;76:453-458.
28. Lip GYH, Zafiris J, Watson RDS, Bareford D, Lowe GDO, Beevers DG. Fibrin D-dimer and β-thromboglobulin as markers of thrombogenesis and platelet activation in atrial fibrillation. Effects of introducing ultra-low-dose warfarin and aspirin. Circulation. 1996;94:425-431.
29. Meade TW, North WRS, Chakrabarti R, Stirling Y, Haines AP, Thompson SG, Brozovie M. Haemostatic function and cardiovascular death: early results of a prospective study. Lancet. 1980;i:1050-1054.
30. Resch KL, Ernst E. The complex impact of fibrinogen on atherosclerosis-related diseases. In: Koenig W, Hombäck V, Bond MG, Dramsch DM, eds. Progression and Regression of Atherosclerosis. Vienna: Blackwell MZV,1995;36-40.
31. Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl Med. 1984;311:501-505.
32. Lowe GDO, Lee AJ, Rumley, A, Price JF, Fowkes FG. Blood viscosity and risk of cardiovascular events: the Edinburgh Artery Study. Br J Haematol. 1997;96:168-173.
33. Tanne D, Benderly M, Boyko V, et al. Fibrinogen is an independent predictor of stroke-TIA in patients with coronary heart disease. Blood Coagul Fibrinolysis. 1994;5(Suppl 2); Abstract 0-52.
34. Banton D, Sweetnam P, Baker I, Elwood P. Peripheral vascular disease. Consequence for survival and association with risk factors in the Speedwell Prospective Heart Disease Study. Br Heart J. 1994;72:128-132.
35. Montalescot G, Ankri A, Vicant E, Drobinski G, Grosgogeat Y, Thomas D. Fibrinogen after coronary angioplasty as a risk factor for restenosis. Circulation. 1995;92:31-38.
36. Stein D, Schoebel FC, Heins M, et al. Lipoprotein(a) and fibrinogen in restenosis after percutaneous transluminal coronary angioplasty. Clin Hemorheol. 1995;15:737-747.
37. Wiseman S, Kenchington G, Dain R, Marshall CE, McCollum CN, Greenhalgh RM, Powell JT. Influence of smoking and plasma factors on patency of femoropopliteal vein grafts. Br Med J. 1989;299:643-646.
38. Grotta JC, Yatsu TM, Pettigrew LC, Rhoades H, Bratina P, Vital D, Alam R, Earls R, Picone C. Prediction of carotid stenosis progression by lipid and hematologic measurements. Neurology. 1989;39:1325-1331.
39. Lee AJ, Mowbray PI, Lowe GDO, Rumley A, Fowkes FGR, Allan PL. Blood viscosity and elevated carotid ultima-media thickness in men and women: the Edinburgh Artery Study. Circulation. 1998;97:1467-1473.
40. Lee AJ, Smith WCS, Lowe GDO, Tunstall-Pedoe H. Plasma fibrinogen and coronary risk factors: the Scottish Heart Health Study. J Clin Epidemiol. 1990;43:913-919.
41. Lee AJ, Lowe GDO, Smith WCS, Tunstall-Pedoe H. Plasma fibrinogen in women: relationships with oral contraception, the menopause and hormone replacement therapy. Br J Haematol. 1993;83:616-621.
42. Lee AJ, Lowe GDO, Woodward M, Tunstall-Pedoe H. Fibrinogen in relation to personal history of prevalent hypertension, diabetes, stroke, intermittent claudication, coronary heart disease and family history: the Scottish Heart Health Study. Br Heart J. 1993;69:338-342.
43. Tunstall-Pedoe H, Woodward M, Tavendale R, D'A Brook R, McCluskey MK. Comparison of the prediction by 27 different risk factors of coronary heart disease and death in men and women of the Scottish Heart Health Study. BMJ. 1997;315:722-729.
44. International Task Force. Prevention of coronary heart disease: scientific background and new clinical guidelines. Recommendations of the European Atherosclerosis Society. Nutr Metabol Cardiovasc Dis. 1992;2:113-565.
45. Rumley A, Lowe GDO, Norrie J Ford I, Shepherd J, Cobbe SM. Blood rheology and outcome in the west of Scotland coronary prevention study. Br J Haematol. 1997;97(Suppl 1):78.
46. th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task force 5. Stratification of patients into high, medium and low risk sub-groups for purposes of risk factor management. J Am Coll Cardiol. 1996;27(5):1007-1019.
47. Lowe G.D.O. Prediction of postoperative deep vein thrombosis. Thromb Haemost. 1997;78:47-52.
48. Reid D. 1991. The clinical role of fibrinogen and fibrin in peripheral arterial disease. MD Thesis, University of Glasgow.
49. Al-Zahrani H, Lowe GDO, Douglas JT, et al. Increased fibrin turnover in peripheral arterial disease: comparison with a population study. Clin Hemorheol. 1992;12:867-872.
50. Smith FB, Lowe GDO, Fowkes FGR, Rumley A, Rumley AG, Donnan PT, Housley E. Smoking, haemostatic factors and lipid peroxides in a population case-control study of peripheral arterial disease. Atherosclerosis. 1993;102:155-162.
51. Rumley A, Woodburn KR, Lowe GDO, et al. Correlation between plasma fibrinogen, fibrin degradation products, and the angiographic extent of peripheral arterial occlusive disease. Blood Coag Fibrinolysis. 1994;5(Suppl 2):38.
52. Lee AJ, Fowkes FGR, Lowe GDO, Rumley A Fibrin D-dimer, haemostatic factors and peripheral arterial disease. Thromb Haemost. 1995;74:828-832.
53. Lee AJ, Fowkes FGR, Lowe GDO, Rumley A. Determinants of fibrin D-dimer in the Edinburgh Artery Study. Arterioscler Thromb Vasc Biol. 1995;15:1094-1097.
54. Sweetnam PM, Thomas HF, Yarnell JWG, Beswick AD, Baker IA. Elwood PC. Fibrinogen, viscosity and the 10-year incidence of ischaemic heart disease. The Caerphilly and Speedwell studies. Eur Heart J. 1996;17:1814-1820.
55. Lee AJ, Fowkes FGR, Lowe GDO, Rumley A. Haemostatic factors, atherosclerosis and risk of abdominal aortic aneurysm. Blood Coagul Fibrinolysis. 1996;7:695-701.
56. Lip GYH, Rumley A, Dunn FG, Lowe GDO. Plasma fibrinogen and fibrin D-dimer in patients with atrial fibrillation: effects of cardioversion to sinus rhythm. Int J Cardiol. 1995;51:245-251.
57. Nieuwenhuizen W. Biochemistry and measurement of fibrinogen. Eur Heart J. 1995;16,(suppl. A):6-10.
58. de Maat MPM, Lowe GDO, Haverkate F. Fibrinogen. In: Laboratory Techniques in Thrombosis, A Manual. 2d rev ed of ECAT Assay Procedures. Jespersen J, Bertina RM, Haverkate F, eds. Dordrecht: Kluwer 1999;79-88.
59. Lowe GDO, Rumley A, Woodward M, Morrison CE, Philippou H, Lane DA, Tunstall-Pedoe H. Epidemiology of coagulation factors, inhibitors and activation markers: The Third Glasgow MONICA Survey. I. Illustrative reference ranges by age, sex and hormone use. Br J Haematol. 1997;97:775-784.
60. Woodward M, Lowe GDO, Rumley A, Tunstall-Pedoe H, Philippou H, Lane A, Morrison CE. Epidemiology of coagulation factors, inhibitors and activation markers: The Third Glasgow MONICA Survey. II. Relationships to cardiovascular risk factors and prevalent cardiovascular disease. Br J Haematol. 1997;97:785-797.
61. Rosenson RS, Tangrey CC, Hafner JM. Intra-individual variability of fibrinogen levels and cardiovascular risk profile. Arterioscler Thromb Vasc Biol. 1994;14:1928-1932.
62. Niewenhuizen W, Bos R. Soluble fibrin and degradation products of fibrinogen (Fg DP), fibrin (FbDP; D-dimer) and total of FgDP and FbDP (TDP). In: Laboratory Techniques in Thrombosis, A Manual. 2d rev ed of ECAT Assay Procedures. Jespersen J, Bertina RM, Haverkate F, eds. Dordrecht: Kluwer; 1999:275-284.